Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients

Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model

(2010) L.I. Cortínez et al.   BRITISH JOURNAL OF ANAESTHESIA

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

(2010) Michael J. Hanley et al.   CLINICAL PHARMACOKINETICS

Obesity, Inflammation, and Cardiovascular Risk

(2010) P Mathieu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A two-compartment effect site model describes the bispectral index after different rates of propofol infusion

(2010) Marcus A. Björnsson et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetic models for propofol—defining and illuminating the devil in the detail

(2009) A.R. Absalom et al.   BRITISH JOURNAL OF ANAESTHESIA

Pharmacology of Morphine in Obese Patients

(2009) Célia Lloret Linares et al.   CLINICAL PHARMACOKINETICS

No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients

(2009) Luca La Colla et al.   EUROPEAN JOURNAL OF ANAESTHESIOLOGY

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

(2009) Prospective Studies Collaboration   LANCET

Encouraging the Move Towards Predictive Population Models for the Obese Using Propofol as a Motivating Example

(2009) Sarah C. McLeay et al.   PHARMACEUTICAL RESEARCH

Lean body mass normalizes the effect of obesity on renal function

(2008) Sarayut Janmahasatian et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY